Business
SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland, July 24, 2024
About this update from Sophia Genetics Sa
[{"type":"text","content":"OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™\n BOSTON and ROLLE, Switzerland, July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities. OncoHelix will be live on MSK-ACCESS® powered with SOPHiA DDM™ later this summer.\n OncoHelix is based in Calgary, Canada, and offers specialized genomic and molecular testing services globally. OncoHelix works in partnership with the Hematology Translational Lab (HTL) at the University of Calgary and has helped significantly advance the University's precision oncology and immunology research pipelines.\n \"Our mission at OncoHelix is to offer exceptional clinical-grade molecular and immune profile testing. That mission is predicated on using the most cutting-edge technology to allow for the rapid validation of genomic panels, sequencing, and analysis,\" said Dr. Pinaki Bose, co-founder and Executive Vice President, OncoHelix. \"The SOPHiA DDM™ Platform has supported our mission over the last year, and we look forward to implementing MSK-ACCESS® powered with SOPHiA DDM™ to advance our liquid biopsy offering.\"\n Liquid biopsy testing provides an alternative testing method to traditional solid tumor biopsy, which can be especially helpful when patients are facing limitations such as insufficient material or poor tissue quality, or simply need a less invasive method of biopsy. Liquid biopsy testing extracts cell-free DNA (cfDNA) from blood plasma, revealing circulating tumor DNA (ctDNA). This approach, obtained through a simple blood draw, expedites clinical decisions, accelerates results for researchers and clinicians, and streamlines monitoring.\n \"OncoHelix has quickly become a trusted leader in precision oncology testing and that is due, in part, to its unrelenting focus on offering the most advanced technology solutions on the market,\" said John Carey, Managing Director, NORAM, SOPH...